Episealer® publication available online
Episurf Medical (Nasdaq: EPIS B) today communicates that the publication Patient-specific implants for focal cartilage lesions in the knee: implant survivorship analysis up to seven years post-implantation, by L. Ryd, K. Flodström and M. T. Manley, which focuses on survival data for 682 Episealer® knee implants implanted between 2012 and 2020, and which has been accepted for publication in the peer-reviewed journal Surgical Technology International, is now available online.
Link to the publication: http://surgicaltechnology.com/OpenAccess/1384-Ryd-OS-FINAL-cr.pdf
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.